|
ZBTB3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.85169999999957E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.60915999999345E-05 |
| Normal-vs-Stage2 |
2.763400E-03 |
| Normal-vs-Stage3 |
2.61279999969055E-07 |
| Normal-vs-Stage4 |
1.21280000042745E-07 |
| Stage1-vs-Stage2 |
1.029990E-01 |
| Stage1-vs-Stage3 |
6.065800E-02 |
| Stage1-vs-Stage4 |
4.109800E-02 |
| Stage2-vs-Stage3 |
4.757300E-03 |
| Stage2-vs-Stage4 |
2.215000E-03 |
| Stage3-vs-Stage4 |
5.534400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.73990000032987E-07 |
| Normal-vs-AfricanAmerican |
2.018500E-04 |
| Normal-vs-Asian |
8.795400E-04 |
| Caucasian-vs-AfricanAmerican |
6.468600E-01 |
| Caucasian-vs-Asian |
1.076110E-02 |
| AfricanAmerican-vs-Asian |
2.403200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.97765999999655E-05 |
| Normal-vs-Female |
1.50409999999379E-06 |
| Male-vs-Female |
6.097800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.44570000002198E-06 |
| Normal-vs-Age(41-60Yrs) |
1.58525999999215E-05 |
| Normal-vs-Age(61-80Yrs) |
3.28329999998989E-06 |
| Normal-vs-Age(81-100Yrs) |
2.942100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.290000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.715400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.165390E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.332600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.520100E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.697370E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.615200E-04 |
| Classical-VS-Follicular |
1.483360E-01 |
| Classical-VS-Other |
8.232000E-01 |
| Classical-VS-Normal |
3.53730000002273E-06 |
| Tall-VS-Follicular |
1.377340E-04 |
| Tall-VS-Other |
4.682600E-01 |
| Tall-VS-Normal |
3.88529997064069E-09 |
| Follicular-VS-Other |
4.855800E-01 |
| Follicular-VS-Normal |
3.380300E-04 |
| Other-VS-Normal |
4.420300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.14579999999942E-05 |
| Normal-vs-N1 |
3.80880005312889E-09 |
| N0-vs-N1 |
4.18079999999765E-05 |
|
|
